Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
The EU recommendation for odronextamab comes after a US rejection in March.
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.